Lantheus Holdings has a Cash Ratio of 3.80. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Lantheus Holdings's Cash Ratio or its related term are showing as below:
LNTH'
s Cash Ratio Range Over the Past 10 Years
Min: 0.8 Med: 1.52 Max: 3.81
Current: 3.8
During the past 13 years, Lantheus Holdings's highest Cash Ratio was 3.81. The lowest was 0.80. And the median was 1.52.
LNTH's Cash Ratio is ranked better than 88.4% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs LNTH: 3.80
Lantheus Holdings Cash Ratio Historical Data
The historical data trend for Lantheus Holdings's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lantheus Holdings's Cash Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings's Cash Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (NAS:LNTH) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lantheus Holdings Cash Ratio Related Terms
Thank you for viewing the detailed overview of Lantheus Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LNTH has been successfully added to your 